Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Inclusion criteria

• Male or female patients 18 - 85 years of age.
• Signed and dated informed consent document.
• Major abscess, surgical site infection, traumatic wound infection or cellulitis suspected or confirmed to be caused by Gram-positive bacteria.
• At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign of infection.
• Requires a minimum of 3 days of IV therapy.
• Patient willing and able to comply with study procedures.

Exclusion criteria

Patients presenting with any of the following:

• A contra-indication to any required study drug.
• Pregnant or nursing females.
• Sustained shock.
• Participation in another study of an investigational drug or device within 30 days.
• Receipt of a systemically or topically administered antibiotic within 14 days prior to randomization, except receipt of a single dose of a short-acting antibacterial drug 3 or more days prior to randomization.
• Infection due to a dalbavancin or vancomycin-resistant organism.
• Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, and/or endovascular infection.
• Exclusively gram-negative bacterial or a fungal ABSSSI.
• Venous catheter infection.
• Infection of a diabetic foot ulcer or a decubitus ulcer.
• Device-related infections.
• Gram-negative bacteremia.
• Infected burns.
• Infected limb with critical ischemia.
• Superficial/simple skin and skin structure infections.
• Concomitant condition requiring non-study antibacterial therapy.
• ABSSSI requiring therapy for longer than 14 days.
• Adjunctive therapy with hyperbaric oxygen.
• More than 2 surgical interventions for ABSSSI anticipated.
• Chronic inflammatory condition precluding assessment of clinical response.
• Absolute neutrophil count < 500 cells/mm3.
• Human immunodeficiency virus (HIV) infection with a CD4 cell count < 200 cells/mm3.
• Recent bone marrow transplant, > 20 mg prednisolone per day (or equivalent) or receiving immunosuppressant drugs after organ transplantation.
• Regular, chronic antipyretic use in patients unable to modify during the first three days of study drug therapy.
• Life expectancy less than 3 months.
• Conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.
• Prior participation in the study.